KASID
Articles
- Page Path
- HOME > Intest Res > Volume 24(1); 2026 > Article
-
Original Article
IBD Comparative short-term efficacy of upadacitinib versus tofacitinib for ulcerative colitis: a 24-week real-world study in Japan -
Akiko Tamura
, Hiromichi Shimizu, Toshimitsu Fujii, Ami Kawamoto, Ryo Morikawa, Shuji Hibiya, Kento Takenaka, Masakazu Nagahori, Kazuo Ohtsuka, Ryuichi Okamoto -
Intestinal Research 2026;24(1):95-102.
DOI: https://doi.org/10.5217/ir.2024.00187
Published online: March 20, 2025
Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan JFIF d d Ducky d qhttp://ns.adobe.com/xap/1.0/ |er˭|I|-fGK.rΛp8XV1%K6mvG+tc+qE &ǸC_Nm:l=_/m5^[dߌڇ.c<%:)tQ$Ow~-aY;UJ >=F)2[nk؆?훐 M=l6[4(O.]2#-H^n#->&mp5~Fӛ+|| S,xag% qkEUzUgæBhߕP(7]kFnq?֖Cpru Z6*rEڊtS|*tI*E}7R<,nUU֫^I7Q*mSly%rdȓd8hE<9oHhMfNSRj[i7D[Rj݊+kდq{"$$H?p \̅S?㭻;t~ R߁ )^/>Qj`yt[w ԛ;² ~+ ߔ_ YW~|o] ?x^ᯛ `ʼn;g)T@vWn]>&4l p+$D̢1l|ȨF%-} .9[}w~
ԠLM9hСablfe&QoW !s ?wjLK?s7yO>(=C~_nyǜu? v 3vyo oI@qV-jeES^[9WoSܝh"l2C1a͔CiJ@3:Pճw= /7ovuk+\V;lDgն <[A+r X~d;m!_s8ݖ;;.0llUC+?i#_crʙ1~C.\q u l8Hܶ2m`ܻM3Tov|Bs rɵ"oLS-
DКw=Tv@f '6|YlD͓Y%-#Ѯo%:&!3o%\J<02;K87>^vgƓ# ;ݝmz^Y6=PS39U%~
&f#
}o!muH; ʲŇ˷yvP+&.7e[3'vR4Yj̗IZ`e˽3o[WU{
m[sUbۋZǾۆl6~9'V*.\S2<Sd*zY[aŶ`]C$n.v^Ʌ
dng>ەZ,Mmϑ :n6nϦezW qUJ4! ۇ4R! =>>F n|Q[{pRO 17ƕ~._I ''00k=b՛o}Osðc2'o\3}ݭQ^ 2 . R1yKȣtAݿ-u ܾw!`?1Whn|gzU o[ECWwjUIן)^h#1ɭ!/Z
np;o;ΗŻkXs."6E`Z1
עӐ9Kl8qd q} 2Stt;#j>;խabONŗ=fwP1j)l6J̶|gV 2`y/0E˛6+ԫ1?
6}KW c\KoKͨ2ۅFws*TԞLיuDx .kCzWXhy۶gLu|%TnupǺl-S* P RaLnT+c+*xl.v!.U=|; !_L̎뱚U=4hm:ٯ"y)$:>%(n}X'p[ȴ
^˒4kƓmzDx
\
'Nq amP7nyN݅=
Correspondence to Hiromichi Shimizu, Department of Gastroenterology and Hepatology, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. E-mail: hshigast@tmd.ac.jp
• Received: November 14, 2024 • Revised: February 4, 2025 • Accepted: February 10, 2025
© 2026 Korean Association for the Study of Intestinal Diseases.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
-
Background/Aims
- Tofacitinib and upadacitinib are small-molecule compounds that inhibit the Janus kinase pathway for the treatment of refractory ulcerative colitis. Only a few reports have compared the efficacy and safety of these 2 drugs in real-world practice. We aimed to show our real-world evidence of these drugs and compare the efficacy and safety profiles in the treatment of ulcerative colitis.
-
Methods
- This study is a single-center retrospective analysis. Patients treated with tofacitinib or upadacitinib at our hospital between June 2018 and January 2024 who were monitored for 24 weeks were included. The primary outcome was steroid-free clinical remission at 24 weeks. Secondary outcomes were response and remission rates at each time point, time series changes in partial Mayo scores and laboratory results, treatment survival at 24 weeks, and the incidence of adverse events.
-
Results
- A total of 68 patients treated with tofacitinib and 34 patients treated with upadacitinib were included. Steroid-free clinical remission rate at 24 weeks was significantly higher in upadacitinib-treated patients than in tofacitinibtreated patients (64.7% vs. 38.2%). The response rates in upadacitinib-treated patients exceeded 60% after 8 weeks of treatment through to 24 weeks, and the rates were higher than those in tofacitinib-treated patients. The incidences of adverse events were 79.4% in upadacitinib-treated patients and 38.2% in tofacitinib-treated patients. The most common adverse event was acne for upadacitinib.
-
Conclusions
- Upadacitinib was more effective than tofacitinib in inducing remission in ulcerative colitis patients. The incidence of adverse events was significantly higher with upadacitinib than tofacitinib.
INTRODUCTION
METHODS
RESULTS
DISCUSSION
-
Funding Source
The authors received no financial support for the research, authorship, and/or publication of this article.
-
Conflict of Interest
No potential conflict of interest relevant to this article was reported.
-
Data Availability Statement
All data in the study can be provided upon request.
-
Author Contributions
Conceptualization; Data curation; Formal analysis: Tamura A, Shimizu H. Investigator: Tamura A. Methodology: Tamura A, Shimizu H. Project administration: Fujii T, Shimizu H. Resources: Tamura A, Shimizu H. Supervision: Fujii T, Nagahori M, Ohtsuka K, Okamoto R. Validation: Morikawa R, Hibiya S, Takenaka K. Visualization: Tamura A, Shimizu H. Writing - original draft: Tamura A, Shimizu H. Writing - review & editing: Kawamoto A. Approval of final manuscript: all authors.
NOTES
Supplementary Material
Supplementary Fig. 1.
Fig. 2.Remission and response rates in the whole cohort. (A) Remission rates at 24 weeks of tofacitinib (n=68) and upadacitinib (n=34). Time series data in remission (B) and response (C) rates of tofacitinib (n=68) and upadacitinib (n=34) up to 24 weeks. Statistical significance was analyzed using a Fisher exact test; aP<0.05, bP<0.01. NS, not significant.
Fig. 3.Remission and response rates in patients exposed to multiple advanced therapies. (A) Remission rates at 24 weeks of tofacitinib (n=41) and upadacitinib (n=2). Time series data in remission (B) and response (C) rates of tofacitinib (n=41) and upadacitinib (n=27) up to 24 weeks. Statistical significance was analyzed using a Fisher exact test; aP<0.01, bP<0.001. NS, not significant.
Fig. 4.Time series data up to 24 weeks. Partial Mayo score (A), stool frequency subscore, (B) and rectal bleeding subscore (C) in patients who had responded tofacitinib (n=29) and upadacitinib (n=26) at 24 weeks. Data are presented as the mean±standard deviation. Statistical significance was analyzed using the Mann-Whitney U test. NS, not significant.
Fig. 5.Survival curves of patients who continued with either of the treatments up to 24 weeks. Kaplan-Meier curves were drawn using the log-rank (Mantel-Haenszel) test. aP<0.05.
Fig. 6.Adverse event rates during tofacitinib (n=68) and upadacitinib (n=34) therapy. Statistical significance was analyzed using a Fisher exact test; aP<0.001.
Table 1.Background Characteristics of Patients
| Characteristics | Tofacitinib (n = 68) | Upadacitinib (n = 34) | P-value |
|---|---|---|---|
| Male sex | 41 (60.3) | 18 (52.9) | 0.5274 |
| Age (yr)a | 38.8 (27.2–48.9) | 44.2 (27.3–51.1) | 0.4742 |
| Disease duration (yr)a | 7 (3.0–10.7) | 8.3 (3.7–11.3) | 0.7386 |
| Disease type | 0.2334 | ||
| Extended | 47 (69.1) | 28 (82.4) | |
| Left-sided | 21 (30.9) | 6 (17.6) | |
| Partial Mayo score | 6 (4–7) | 6 (5–7) | 0.2667 |
| Mayo endoscopic scoreb | 3 (2–3) | 3 (3–3) | 0.3583 |
| Mayo scoreb | 9 (7–10) | 9 (8–10) | 0.2614 |
| White blood cell counts (× 103/µL) | 6,600 (5,450–9,225) | 6,450 (1,900–24,300) | 0.8170 |
| Hemoglobin (g/dL) | 12.7 (10.7–14.2) | 13.0 (9.2–16.5) | 0.3587 |
| Albumin (g/dL) | 3.8 (3.2–4.1) | 3.9 (1.8–4.7) | 0.4083 |
| C-reactive protein (mg/dL) | 0.42 (0.13–1.94) | 0.42 (0.03–13.20) | 0.7599 |
| Corticosteroid | 0.4883 | ||
| Refractory | 1 (1.5) | 2 (5.9) | |
| Resistance | 28 (41.2) | 14 (41.2) | |
| Dependent | 36 (52.9) | 18 (52.9) | |
| Advanced therapy exposed | 65 (95.6) | 34 (100) | 0.5489 |
| No. of exposed advanced therapy | 0.1141 | ||
| 1 | 24 (35.3) | 7 (20.6) | |
| ≥2 | 41 (60.2) | 27 (79.4) | |
| Janus kinase inhibitor-naïve | 65 (95.6) | 16 (47.1) | < 0.0001c |
Values are presented as number (%) or median (interquartile range).
a The age and disease duration were calculated in months and expressed in years.
b The number of patients in the Mayo endoscopic and Mayo scores are n=33 (tofacitinib) and 18 (upadacitinib).
c Statistical significance was calculated using Mann-Whitney U test and Fisher exact test; P<0.0001.
Table 2.Adverse Events
- 1. Danese S, Grisham M, Hodge J, Telliez JB. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol 2016;310:G155–G162.ArticlePubMedPMC
- 2. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017;376:1723–1736.ArticlePubMed
- 3. Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet 2022;399:2113–2128.ArticlePubMed
- 4. Shimizu H, Fujii T, Hibiya S, et al. Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis. Intest Res 2021;19:115–118.ArticlePubMedPMCPDF
- 5. Taxonera C, Olivares D, Alba C. Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis. Inflamm Bowel Dis 2022;28:32–40.ArticlePubMedPDF
- 6. Biemans VB, Sleutjes JA, de Vries AC, et al. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Aliment Pharmacol Ther 2020;51:880–888.ArticlePubMedPMCPDF
- 7. Honap S, Chee D, Chapman TP, et al. Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience. J Crohns Colitis 2020;14:1385–1393.PubMed
- 8. Chaparro M, Garre A, Mesonero F, et al. Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA Registry. J Crohns Colitis 2021;15:35–42.ArticlePubMedPDF
- 9. Shin SH, Oh K, Hong SN, et al. Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study. Therap Adv Gastroenterol 2023;16:17562848231154103.ArticlePubMedPMCPDF
- 10. Straatmijer T, van Schaik FD, Bodelier AG, et al. Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry. Aliment Pharmacol Ther 2023;57:117–126.ArticlePubMedPMCPDF
- 11. Yu A, Ha NB, Shi B, Cheng YW, Mahadevan U, Beck KR. Real-world experience with tofacitinib dose de-escalation in patients with moderate and severe ulcerative colitis. Clin Gastroenterol Hepatol 2023;21:3115–3124.e3.ArticlePubMed
- 12. Long MD, Afzali A, Fischer M, et al. Tofacitinib Response in Ulcerative Colitis (TOUR): early response after initiation of tofacitinib therapy in a real-world setting. Inflamm Bowel Dis 2023;29:570–578.ArticlePubMedPMCPDF
- 13. Shimizu H, Aonuma Y, Hibiya S, et al. Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study. Intest Res 2024;22:369–377.ArticlePubMedPMCPDF
- 14. Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2022;7:161–170.ArticlePubMed
- 15. Shehab M, Alrashed F, Alsayegh A, et al. Comparative efficacy of biologics and small molecule in ulcerative colitis: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol 2025;23:250–262.ArticlePubMed
- 16. Boneschansker L, Ananthakrishnan AN, Massachusetts General Hospital Crohn’s And Colitis Center Collaborators. Comparative effectiveness of upadacitinib and tofacitinib in inducing remission in ulcerative colitis: real-world data. Clin Gastroenterol Hepatol 2023;21:2427–2429.e1.ArticlePubMed
- 17. Dalal RS, Kallumkal G, Cabral HJ, Barnes EL, Allegretti JR. One-year comparative effectiveness of upadacitinib vs tofacitinib for ulcerative colitis: a multicenter cohort study. Am J Gastroenterol 2024;119:1628–1631.Article
- 18. Akiyama S, Shimizu H, Tamura A, et al. Comparative efficacy and safety of three Janus kinase inhibitors in ulcerative colitis: a real-world multicentre study in Japan. Aliment Pharmacol Ther 2025;61:524–537.ArticlePubMed
- 19. Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021;397:2151–2168.ArticlePubMed
- 20. Hayashi N, Ikeda M, Liu J, et al. Acne among Japanese patients with atopic dermatitis receiving upadacitinib in the phase 3 rising up study. Dermatol Ther (Heidelb) 2023;13:1817–1830.ArticlePubMedPMCPDF
REFERENCES
Figure & Data
REFERENCES
Citations
Citations to this article as recorded by 
- Successful treatment of tofacitinib-refractory scleritis associated with multiple systemic inflammatory diseases using upadacitinib
Kodai Yuge, Nobuyo Yawata, Kenichiro Asahara, Satoshi Yamana, Nobuyuki Ono, Koh-Hei Sonoda
Immunological Medicine.2026; 49(2): 266. CrossRef - Optimizing Janus kinase inhibitor therapy for ulcerative colitis: a real-world perspective
Shintaro Akiyama
Intestinal Research.2026; 24(2): 197. CrossRef - Janus Kinase Inhibitors for Inflammatory Bowel Disease: Concise Questions and Answers on Their Use in Clinical Practice
Javier P Gisbert, María Chaparro
Inflammatory Bowel Diseases.2026; 32(4): 775. CrossRef - Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team
Seung Min Hong, Dong Hyun Kim, June Hwa Bae, Seung Yong Shin, Eun Mi Song, Ji Eun Kim, Young Joo Yang, Jiyoung Yoon, Sang-Bum Kang, Eun Soo Kim, Seong-Eun Kim, Seong-Jung Kim, Jun Lee, Soo-Young Na, Soo Jung Park, Sang Hyoung Park, Miyoung Choi, Myung Ha
Intestinal Research.2026; 24(1): 27. CrossRef - Incidence of acne in patients with inflammatory bowel disease treated with Janus kinase inhibitors: a systematic review and meta-analysis
Mohammed Nabil Quraishi, Maryam A Alahmad, Thaer Khaleel Swaid, Antonio Facciorusso, Alyssa A Grimshaw, Badr Al-Bawardy
Inflammatory Bowel Diseases.2026;[Epub] CrossRef - Semen Discoloration Following Upadacitinib Therapy in Patients with Inflammatory Bowel Disease
Jeong Hwa Lee, Hae Chang Cho, Jae Myung Cha, Byong Duk Ye, Sung Wook Hwang, Eun Soo Kim
Gut and Liver.2026; 20(4): 704. CrossRef - Upadacitinib after tofacitinib in ulcerative colitis
Hyeon Jin Cho, Eun Soo Kim
Intestinal Research.2025; 23(3): 229. CrossRef - Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study
Fabio Salvatore Macaluso, Walter Fries, Anna Viola, Clara De Francesco, Nunzio Belluardo, Emiliano Giangreco, Maria Cappello, Roberto Ajovalasit, Filippo Mocciaro, Barbara Scrivo, Antonino Carlo Privitera, Maria Emanuela Distefano, Alessandro Vitello, Con
Digestive and Liver Disease.2025; 57(11): 2109. CrossRef - Tofacitinib in acute severe ulcerative colitis: review addressing seven key unmet needs
Chuong Dinh Nguyen, Luan Minh Dang, Thong Duy Vo, Hoang Huu Bui, Eun Soo Kim, Joyce Wing Yan Mak, Choon Jin Ooi
Therapeutic Advances in Gastroenterology.2025;[Epub] CrossRef - Upadacitinib versus Tofacitinib in the Management of Ulcerative Colitis: A Systematic Review and Meta-Analysis
Tareq Alsaleh, Abdul Mohammed, Aimen Farooq, Magda Elamin, Amr Akl, Karim Mohamed Yassin, Ahmed Elnaggar, Jennifer Seminerio
Inflammatory Intestinal Diseases.2025; 11(1): 29. CrossRef
PubReader
ePub Link
Cite
XML Download- Figure
-
- Related articles
-
- Optimizing Janus kinase inhibitor therapy for ulcerative colitis: a real-world perspective
- Upadacitinib after tofacitinib in ulcerative colitis
- Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study
- Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study
Comparative short-term efficacy of upadacitinib versus tofacitinib for ulcerative colitis: a 24-week real-world study in Japan
Fig. 1. Flowchart of patients enrolled in this study. pMS, partial Mayo score.
Fig. 2. Remission and response rates in the whole cohort. (A) Remission rates at 24 weeks of tofacitinib (n=68) and upadacitinib (n=34). Time series data in remission (B) and response (C) rates of tofacitinib (n=68) and upadacitinib (n=34) up to 24 weeks. Statistical significance was analyzed using a Fisher exact test; aP<0.05, bP<0.01. NS, not significant.
Fig. 3. Remission and response rates in patients exposed to multiple advanced therapies. (A) Remission rates at 24 weeks of tofacitinib (n=41) and upadacitinib (n=2). Time series data in remission (B) and response (C) rates of tofacitinib (n=41) and upadacitinib (n=27) up to 24 weeks. Statistical significance was analyzed using a Fisher exact test; aP<0.01, bP<0.001. NS, not significant.
Fig. 4. Time series data up to 24 weeks. Partial Mayo score (A), stool frequency subscore, (B) and rectal bleeding subscore (C) in patients who had responded tofacitinib (n=29) and upadacitinib (n=26) at 24 weeks. Data are presented as the mean±standard deviation. Statistical significance was analyzed using the Mann-Whitney U test. NS, not significant.
Fig. 5. Survival curves of patients who continued with either of the treatments up to 24 weeks. Kaplan-Meier curves were drawn using the log-rank (Mantel-Haenszel) test. aP<0.05.
Fig. 6. Adverse event rates during tofacitinib (n=68) and upadacitinib (n=34) therapy. Statistical significance was analyzed using a Fisher exact test; aP<0.001.
Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.
Fig. 6.
Comparative short-term efficacy of upadacitinib versus tofacitinib for ulcerative colitis: a 24-week real-world study in Japan
| Characteristics | Tofacitinib (n = 68) | Upadacitinib (n = 34) | P-value |
|---|---|---|---|
| Male sex | 41 (60.3) | 18 (52.9) | 0.5274 |
| Age (yr) |
38.8 (27.2–48.9) | 44.2 (27.3–51.1) | 0.4742 |
| Disease duration (yr) |
7 (3.0–10.7) | 8.3 (3.7–11.3) | 0.7386 |
| Disease type | 0.2334 | ||
| Extended | 47 (69.1) | 28 (82.4) | |
| Left-sided | 21 (30.9) | 6 (17.6) | |
| Partial Mayo score | 6 (4–7) | 6 (5–7) | 0.2667 |
| Mayo endoscopic score |
3 (2–3) | 3 (3–3) | 0.3583 |
| Mayo score |
9 (7–10) | 9 (8–10) | 0.2614 |
| White blood cell counts (× 103/µL) | 6,600 (5,450–9,225) | 6,450 (1,900–24,300) | 0.8170 |
| Hemoglobin (g/dL) | 12.7 (10.7–14.2) | 13.0 (9.2–16.5) | 0.3587 |
| Albumin (g/dL) | 3.8 (3.2–4.1) | 3.9 (1.8–4.7) | 0.4083 |
| C-reactive protein (mg/dL) | 0.42 (0.13–1.94) | 0.42 (0.03–13.20) | 0.7599 |
| Corticosteroid | 0.4883 | ||
| Refractory | 1 (1.5) | 2 (5.9) | |
| Resistance | 28 (41.2) | 14 (41.2) | |
| Dependent | 36 (52.9) | 18 (52.9) | |
| Advanced therapy exposed | 65 (95.6) | 34 (100) | 0.5489 |
| No. of exposed advanced therapy | 0.1141 | ||
| 1 | 24 (35.3) | 7 (20.6) | |
| ≥2 | 41 (60.2) | 27 (79.4) | |
| Janus kinase inhibitor-naïve | 65 (95.6) | 16 (47.1) | < 0.0001 |
| Adverse events | Tofacitinib (n=68) | Upadacitinib (n = 34) |
|---|---|---|
| Infections | 13 (19.1) | 12 (35.3) |
| Herpes zoster | 1 (1.5) | 2 (5.9) |
| Creatine phosphokinase elevation | 1 (1.5) | 1 (2.9) |
| Dyslipidemia | 6 (8.8) | 1 (2.9) |
| Acne | 1 (1.5) | 16 (47.1) |
| Severe adverse events | 1 (1.5) | 1 (2.9) |
Table 1. Background Characteristics of Patients
Values are presented as number (%) or median (interquartile range). The age and disease duration were calculated in months and expressed in years. The number of patients in the Mayo endoscopic and Mayo scores are n=33 (tofacitinib) and 18 (upadacitinib). Statistical significance was calculated using Mann-Whitney
Table 2. Adverse Events
Values are presented as number (%).
